Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension

BACKGROUND: The evidence regarding triple oral combination therapy for patients with pulmonary arterial hypertension (PAH) is scarce. This study was performed to investigate the effectiveness and safety of triple oral combination therapy with macitentan, riociguat, and selexipag. METHODS: Among cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Momoi, Mizuki, Hiraide, Takahiro, Shinya, Yoshiki, Momota, Hiromi, Fukui, Shogo, Kawakami, Michiyuki, Itabashi, Yuji, Fukuda, Keiichi, Kataoka, Masaharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919213/
https://www.ncbi.nlm.nih.gov/pubmed/33627044
http://dx.doi.org/10.1177/1753466621995048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919213/
https://www.ncbi.nlm.nih.gov/pubmed/33627044
http://dx.doi.org/10.1177/1753466621995048

Ejemplares similares